TVTX FY 2023 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$145M+32.7% YoY

Gross Profit

$134M92.1% margin

Operating Income

-$388M-267.2% margin

Net Income

-$111M-76.7% margin

EPS (Diluted)

$-1.50

Cash Flow

Operating Cash Flow

-$280M

Free Cash Flow

-$322M

Stock-Based Comp.

$44M

Balance Sheet

Total Assets

$789M

Total Liabilities

$588M

Stockholders' Equity

$201M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$145M	$109M	+32.7%
Gross Profit	$134M	$105M	+27.4%
Operating Income	-$388M	-$320M	-21.4%
Net Income	-$111M	-$278M	+60.0%